Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: conbercept, aflibercept, tb-403 | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 25 Parkinson's papers of 6,543 | 0.57 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 4988
Sealed predictions
- PGF in dopamine neurons, braak-0.20 (p 0.607) → -0.87 (p 0.002)receipt 4995
Swarm cases
receipt 4995: PGF in dopamine neurons, braak
- power
- full sample -0.54 (p 0.019, n 18), 95% CI -0.81 to -0.10. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.56 (p 0.016, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.66 (p 0.0030, n 18). not the mix.
- skeptic
- leave-one-out range -0.66 to -0.48, sign flips 0; without severely affected donors -0.54 (p 0.019, n 18). robust.
- cell type
- strongest in astrocytes: -0.61 (p 0.0069, n 18) vs -0.54 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PGF in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up PGF · astrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.07 p 0.790 (needs p < 3.9e-4)
Receipts
loading the receipts